Lucerastat (Standard)

Lucerastat (Standard) is the analytical standard of Lucerastat. This product is intended for research and analytical applications. Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS) . Lucerastat has the potential for Fabry disease study[1][2].

Product Specifications

CAS Number

[141206-42-0]

Product Name Alternative

NB-DGJ (Standard) ; N- (n-Butyl) deoxygalactonojirimycin (Standard)

UNSPSC

12352005

Target

Glucosylceramide Synthase (GCS) ; Reference Standards

Related Pathways

Neuronal Signaling; Others

Field of Research

Metabolic Disease

Smiles

O[C@H]1[C@@H](CO)N(CCCC)C[C@H](O)[C@H]1O

Molecular Formula

C10H21NO4

Molecular Weight

219.28

References & Citations

[1]Sanne J van der Veen, et al. Developments in the Treatment of Fabry Disease. J Inherit Metab Dis. 2020 Feb 21.|[2]R.W.D. Welford, et al. Lucerastat, an Iminosugar for Substrate Reduction Therapy in Fabry Disease: Preclinical Evidence.